Psoriatic Arthritis: New and Emergent Therapies
|
|
- Andrew Haynes
- 6 years ago
- Views:
Transcription
1 Psoriatic Arthritis: New and Emergent Therapies Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA
2 DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Current Consulting/Advisory Board Agreements/or Speakers Bureau: Janssen Inc.; Celgene Corp., Bristol Myers Squibb Co., Beiersdorf, Inc., Abbvie, UCB, Novartis, Incyte, Lilly, Reddy Labs, Valeant, Dermira, Allergan, Sun Pharmaceutical Industries Research/Educational Grants : Janssen, Incyte
3 Agenda Skin Matters IL-17 Blockade Ixekizumab Secukinumab IL-23 Blockade Guselkumab Abatacept Tofacitinib TNF Blockade Data shown will be from only PSA studies except for certolizumab
4 Skin Matters Arthur Kavanaugh, Alice Gottlieb, Akimichi Morita, Joseph Merola, Julie Birt, Chen-Yen Lin, Catherine Shuler, Diamant Thaçi ACR, 2017
5 Assess activity, impact, and prognostic factors NSAIDs and IA corticosteroids as indicated Physiotherapy and NSAIDs Physiotherapy Corticosteroid injections as indicated Topicals as indicated GRAPPA PsA Treatment Recommendations 2015 Assess which domains are involved Peripheral arthritis Axial disease Enthesitis Dactylitis Skin Nails csdmards, TNFi, or PDE-4i Biologics (TNFi, IL12/23i, IL17i) or PDE-4i Switch biologic (TNFi, IL12/23i, or IL17i) NSAIDs only TNFi, IL17i or IL12/23i Switch biologic (TNFi, IL17i or IL12/23i) No direct evidence for therapies in axial PsA; recommendations based on SpA literature NSAIDs Biologics (TNFi, IL12/23i, IL17i) or PDE-4i Switch biologic (TNFi, IL12/23i, IL17i) or PDE-4i CS injections: consider on individual basis due to potential for serious side effects; no clear evidence for efficacy NSAIDS csdmards, or PDE-4i Biologics (TNFi, IL12/23i) Switch biologic, (TNFi, IL12/23i, IL17i) or PDE-4i Topicals Phototx or csdmards or PDE-4i Biologics, (TNFi, IL12/23i, IL17i) or PDE-4i Switch biologic (TNFi, IL12/23i, IL17i) or PDE-4i Topical or procedural or csdmards Biologics, (TNFi, IL12/23i, IL17i) or PDE-4i Switch biologic, (TNFi, IL12/23i, IL17i) or PDE-4i IA=intraarticular; i=inhibitor. Yellow text=conditional recommendations (no current regulatory approval Treat, or periodically based on abstract re-evaluate data only. & Coates Consider LC et previous al. Arthritis therapy, Rheum. patient 2016;68(5): preference, other disease involvement & comorbidities modify Expedited therapy therapeutic as needed route CS: corticosteroid; csdmard: conventional synthetic disease-modifying antirheumatic drug; IA: intra-articular; IL: interleukin; NSAID: nonsteroidal anti-inflammatory drug; PDE-4i: phosphodiesterase-4 inhibitor; PsA: psoriatic arthritis; SpA: spondyloarthropathy; TNFi: tumor necrosis factor inhibitor.
6 Ixekizumab is FDA Approved forpsoriasis INDICATIONS AND USAGE TALTZ is a humanized interleukin-17a antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy DOSAGE AND ADMINISTRATION Administered by subcutaneous injection Recommended dose is 160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks 90% PASI 75, 70% PASI 90, 40% PASI 100 at week 16 FDA: Food and Drug Administration; PASI: Psoriasis Area Severity Index.
7 Ixekizumab is FDA approved for adults with active psoriatic arthritis DOSAGE AND ADMINISTRATION Plaque Psoriasis TALTZ is administered by subcutaneous injection. The recommended dose is 160mg (two 80 mg injections) at Week 0, followed by 80mg at Weeks 2, 4, 6, 8, 10, and 12, then 80mg every 4weeks. Psoriatic Arthritis The recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at week 0, followed by 80 mg every 4 weeks. For psoriatic arthritis patients with coexistent moderate-tosevere plaque psoriasis, use the dosing regimen for plaque psoriasis
8 Clinical Studies Cited in the PSA Package Insert Signs and Symptoms Control at weeks 12 and 24 Inhibition of Radiographic Progression at week 16 Improved Health Related Outcomes and Physical Function at weeks 12 and 16 Decreased CRP at weeks 12 and 16 Improved Dactylitis and Enthesitis (no data shown)
9 At wk 24 Peripheral Arthritis Axial Disease Enthesitis LEI 0% Dactylitis LDI-B%0 Skin %PASI 90 Nails % NAPSI 0 Bio Naïve* -Ixe q 4wks 57.9% ACR20 mtss Placebo 31.1% ACR20% mtss ADA Active control 57.4% ACR 20 mtss (NS) (NS) Bio Exp.** -Ixe q 4wks 53% ACR20 -Placebo 19% ACR20 35 (NS) *Mease et alann Rheum Dis 2016;0:1 9. doi: /annrheumdis , **Nash et al Lancet 2017; 389:
10 Secukinumab is FDA Approved for Psoriasis Indication: for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Dosage: Recommended dose is 300 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks. For some patients, a dose of 150 mg may be acceptable FDA: Food and Drug Administration.
11 Secukinumab is Indicated for PsA in the United States 2.2 Psoriatic Arthritis For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosing and administration recommendations for plaque psoriasis [see Dosage and Administration (2.1)] For other psoriatic arthritis patients, administer secukinumab with or without a loading dosage by subcutaneous injection. The recommended dosage: o o o With loading dosage is 150 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter Without a loading dosage is 150 mg every 4 weeks If a patient continues to have active psoriatic arthritis, consider a dosage of 300 mg Secukinumab may be administered with or without methotrexate Package Insert. PsA: psoriatic arthritis.
12 IL-23 Blockade: Guselkumab PSA Phase 2 Clinical Trial
13 Guselkumab is FDA-approved for Psoriasis Indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy Dosing: 100 mg sq at weeks 1,4 and every 8 weeks
14 Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo- Controlled Study Atul A. Deodhar 1, Alice B Gottlieb 2, Wolf-Henning Boehncke 3, Bin Dong 4,Yuhua Wang 4, William Barchuk 5, Xie Xu 5, Elizabeth C. Hsia 4 1 Oregon Health & Science University, Portland, OR, USA; 2 Department of Dermatology, New York Medical College, Valhalla, NY, USA; 3 Department of Dermatology, Geneva University Hospital, Geneva, Switzerland, 4 Janssen Research & Development, LLC, Spring House, PA, USA; 5 Janssen Research & Development, LLC, San Diego, CA, USA, ACR,2016 Originally presented at ACR 2016 This presentation was supported by Janssen Research & Development, LLC
15 Presentation number: OP0223 Abatacept in the Treatment of Active Psoriatic Arthritis: 1-year Results From a Phase III Study P Mease, 1 AB Gottlieb, 2 D van der Heijde, 3 O FitzGerald, 4 A Johnsen, 5 M Nys, 6 S Banerjee, 5 D Gladman 7 1 Swedish Medical Center and University of Washington, Seattle, WA, USA; 2 New York Medical College, Valhalla, NY, USA; 3 Leiden University Medical Center, Leiden, Netherlands; 4 St Vincent s University Hospital and University College Dublin, Dublin, Ireland; 5 Bristol-Myers Squibb, Princeton, NJ, USA; 6 Bristol-Myers Squibb, Braine-l Alleud, Belgium; 7 University of Toronto and Toronto Western Hospital, Toronto, ON, Canada EULAR Annual European Congress of Rheumatology June 2017 Madrid, Spain
16 Introduction Unmet need exists for new targeted therapies for PsA PsA susceptibility is associated with Class I MHC molecules that are involved in antigen presentation to T cells 1 T cells are implicated in disease pathogenesis Abatacept, a selective T-cell co-stimulation modulator, 2 is a potential therapy for PsA with a distinct mechanism of action upstream of currently available agents 3 Abatacept is an approved treatment for RA with >10 years post-marketing experience CD80/86 Co-stimulatory pathway CD28 Abatacept Fully human soluble fusion protein Works early in the inflammatory process to reduce T-cell activation APC T cell MHC T-cell receptor APC=antigen-presenting cell; MHC=major histocompatibility complex; PsA=psoriatic arthritis 1. FitzGerald O, et al. Arthritis Res Ther 2009;11:214; 2. Cutolo M, et al. Autoimmun Rev 2013;12:758 67; 3. Ramiro S, et al. Ann Rheum Dis 2016;75: Figure adapted from Kremer JM. J Clin Rheumatol 2005;11:S55 62
17 Study Design Screening (7 42 days) Day 1 Randomization stratified by: MTX use prior TNFi use plaque psoriasis 3% BSA Double-blind phase Placebo SC weekly Abatacept 125 mg SC weekly Week 16 Early escape to open-label if <20% improvement in joint counts Week 24 1 Endpoint: ACR20 Open-label phase Abatacept 125 mg SC weekly Week 44 End of early escape open-label phase Week 52 Eligibility criteria Age 18 years Met CASPAR criteria Active arthritis ( 3 swollen and 3 tender joints) Active plaque psoriasis with 1 qualifying target lesion 2 cm in diameter Inadequate response or intolerance to 1 non-biologic DMARD May have failed TNFi agents Sample size calculation assumptions Estimates based on results of Phase II study of abatacept in PsA 1 BSA=body surface area; SHS=Sharp/van der Heijde score; TNFi=tumour necrosis factor inhibitor 1. Mease P, et al. Arthritis Rheum 2011;63:939 48
18 Baseline Patient Characteristics Data are mean (SD) unless indicated otherwise *n=124; n=123 Abatacept (n=213) Placebo (n=211) Age, years 51.0 (10.7) 49.8 (11.3) Female, n (%) 121 (56.8) 112 (53.1) Region, n (%) South America Europe North America Rest of World 95 (44.6) 53 (24.9) 44 (20.7) 21 (9.9) 80 (37.9) 59 (28.0) 40 (19.0) 32 (15.2) Prior TNFi, n (%) 129 (60.6) 130 (61.6) Concomitant MTX, n (%) 129 (60.6) 127 (60.2) MTX weekly dose, mg 17.1 (7.0)* 17.1 (9.2) Concomitant oral corticosteroid, n (%) 56 (26.3) 51 (24.2) PsA duration, years 8.3 (8.1) 8.8 (8.3) Psoriasis 3% BSA, n (%) 146 (68.5) 148 (70.1) Enthesitis, n (%) 140 (65.7) 132 (62.6) Dactylitis, n (%) 61 (28.6) 50 (23.7)
19 Baseline Disease Characteristics Abatacept (n=213) Placebo (n=211) TJC (13.4) 19.3 (13.1) SJC (7.8) 11.1 (7.2) DAS28 (CRP) 5.0 (1.1) 4.9 (1.1) Leeds Enthesitis Index (range: 0 6) 2.1 (2.0) 1.9 (2.0) Leeds Dactylitis Index Basic 20.3 (56.0) 16.9 (45.7) PASI in patients with psoriasis 3% BSA 7.4 (8.0) 7.2 (7.8) HAQ-DI 1.3 (0.7) 1.3 (0.7) Total SHS, PsA-modified 20.0 (46.8) 17.7 (39.6) CRP, mg/l 14.0 (20.9) 14.3 (30.3) Elevated CRP >ULN (3 mg/l), n (%) 146 (68.9) 131 (62.7) Data are mean (SD) unless indicated otherwise Patient numbers in the abatacept and placebo arms were 210 and 208 for DAS28 (CRP), 145 and 148 for PASI, 212 and 211 for HAQ-DI, 205 and 202 for PsA-modified total SHS, and 212 and 209 for elevated CRP PASI=Psoriasis Area and Severity Index; ULN=upper limit of normal
20 Abatacept At week 24 Peripheral Arthritis Axial Disease Enthesitis- % Complete Resolution Dactylitis-% Complete Resolution Skin %PASI75 Nails Abatacept 39.4 % ACR20; %non progression xray 42.7% 32.9% complete resolution 44.3% complete resolution 16.4% PBO % 22.3 ACR 20; %non progression xray 32.7% 21.7% complete resolution 34.0% complete resolution 10.1% Peripheral Arthritis p <0.001; All others could not be analyzed because in hierarchy they were below HAQ-DI which did not meet statistical significance. Philip Mease, Alice B Gottlieb, Désirée van der Heijde, Oliver FitzGerald, Alyssa Johnsen,Marleen Nys,Subhashis Banerjee, Dafna Gladman:ARD Online First, published on May 4, 2017 as /annrheumdis
21 Tofacitinib JAK kinase inhibitor FDA approved for rheumatoid arthritis
22
23
24 3 months Except xray data Biologics Naive Peripheral Arthritis: % ACR 20/% Non progression on mtss at 12 months Axial ND Enthesitis Change in LEI Index Dactylitis Change in dactylitis score 5 mg BID 50/ NS mg BID 61/ Adalimumab 55/ Placebo (x 3 months) 33 /xrays not done for placebo at 12 months Skin % PASI 75 Nails ND Mease et al NEJM 377: , 2017; Inhibition of radiographic progression at 12 months; all patients on a cdmard; adalimumab = active control; no stats on dactylitis and xray non progression
25 TNF- Blockers
26 Comparative Data at Primary Endpoint Adalimumab Etanercept Infliximab Golimumab/ Certolizumab % PASI (tested in only PSA)/80 (PSO) % ACR /58 Safety (Perceived) Adalimumab (A), Etanercept (E), Certolizumab and Infliximab (I) are FDA approved for controlling signs and symptoms, inhibition of radiographic progression and improvement of quality of life in PSA; A, E, I also for moderate to severe psoriasis. Golimumab is FDA approved for controlling signs and symptoms in PSA
27 Conclusion Class Peripheral Arthritis: Signs/Symptoms Inhibition of XRAY Progression Enthesitis Dactylitis Skin Nails IL-17 Mabs yes yes yes yes 4+ Yes IL-23 Mab yes? yes yes 4+ Probably yes Tofacitinib yes??yes?yes 1-2+?yes Abatacept yes??? no? TNF inhibitors yes yes yes yes yes
Rheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationNEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes
Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes Madrid, Spain,
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationchemotherapeutic agents in
Use of biologics and chemotherapeutic agents in cutaneous emergencies: Focus on lifethreatening forms of psoriasis Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan
More informationIxekizumab. Η νέα θεραπευτική προςέγγιςη ςτη ΨΑ μέςω τησ αναςτολήσ τησ IL-17A. Απρίλιοσ 2018 ΕΠΕΜΥ Πόρτο Χέλι
Ixekizumab Η νέα θεραπευτική προςέγγιςη ςτη ΨΑ μέςω τησ αναςτολήσ τησ IL-17A Απρίλιοσ 218 ΕΠΕΜΥ Πόρτο Χέλι ΣΑΜΑΣΗ-ΝΙΚΟ ΛΙΟΗ Καθηγ. Ρευματολογίας Ιατρική χολή Παν. Πατρών Ixekizumab Στοιχεία για το mab
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More information5/4/2018. Disclosures. PsA: A heterogeneous disease. Objectives. PsA: A heterogeneous disease Fatigue
5//18 Disclosures Management of Psoriatic Arthritis Alexis Ogdie, MD MSCE Assistant Professor of Medicine and Epidemiology Director, Penn Psoriatic Arthritis Clinic Division of Rheumatology Center for
More informationUniversity of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationcertolizumab pegol (Cimzia )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationSIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Commercial Medical Benefit Drug Policy SIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION Policy Number: PHA031 Effective Date: March 1, 2019 Table of Contents Page COVERAGE RATIONALE...
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationintolerance to tumour necrosis
To cite: Nash P, Behrens F, Orbai A-M, et al. Ixekizumab is efficacious when used alone or when added to conventional synthetic diseasemodifying antirheumatic drugs (cdmards) in patients with active psoriatic
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab
ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents ORENCIA demonstrated comparable
More informationPGA x BSA as a PASI Surrogate
PGA x BSA as a PASI Surrogate Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationSynopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier
Module 5.3 Protocol: EudraCT No.: 2005-003525-92 Title of the study: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept
More informationCosentyx clinical trial program in spondyloarthritis (SpA) 1-7
Cosentyx clinical trial program in spondyloarthritis (SpA) 1-7 There are five pivotal trials; three in psoriatic arthritis, two in ankylosing spondylitis More than 10,000 patients have been treated with
More informationIxekizumab improves patient-reported outcomes up to 52 weeks in bdmard-naïve patients with active psoriatic arthritis (SPIRIT-P1)
RHEUMATOLOGY Original article Rheumatology 2018;57:1777 1788 doi:10.1093/rheumatology/key161 Advance Access publication 25 June 2018 Ixekizumab improves patient-reported outcomes up to 52 weeks in bdmard-naïve
More informationTNF Inhibitors: Lessons From Immunogenicity
TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:
More informationSwitching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence
Drugs R D (2017) 17:509 522 DOI 10.1007/s40268-017-0215-7 REVIEW ARTICLE Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence Luisa Costa 1 Carlo Perricone 2 Maria Sole
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationGolimumab: a novel anti-tumor necrosis factor
Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationSecukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
Rheumatol Ther (2018) 5:99 122 https://doi.org/10.1007/s40744-018-0106-6 ORIGINAL RESEARCH Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationOpinion 1 October 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2014 CIMZIA 200 mg, solution for subcutaneous injection 1 B/2 1 ml prefilled syringes with needle guard
More informationADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationProper treatment of psoriatic arthritis (PsA) requires. Update on Treatment of Psoriatic Arthritis. Philip Mease, M.D.
167 Update on Treatment of Psoriatic Arthritis Philip Mease, M.D. Abstract Some of this past year s key papers or abstracts on psoriatic arthritis (PsA) assessment and treatment are reviewed in this paper.
More informationCosentyx clinical trial program in spondyloarthritis (SpA) 1-5
Cosentyx clinical trial program in spondyloarthritis (SpA) 1-5 There are four pivotal trials; two in psoriatic arthritis, two in ankylosing spondylitis More than 10,000 patients have been treated with
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationHelliwell et al. Arthritis Research & Therapy (2018) 20:242
Helliwell et al. Arthritis Research & Therapy (2018) 20:242 https://doi.org/10.1186/s13075-018-1739-0 RESEARCH ARTICLE Open Access Disease-specific composite measures for psoriatic arthritis are highly
More information3 rd Appraisal Committee meeting, 28 February 2017 Committee D
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple Technology Appraisal 3 rd Appraisal Committee
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1017-7 Program Prior Authorization/Notification Medication Cimzia (certolizumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationWhat I Have Learned Over the Years - Keystone s Top 10 -
What I Have Learned Over the Years - Keystone s Top 10 - Edward Keystone, MD FRCP(C) Professor of Medicine University of Toronto, CANADA Ontario Rheumatology Association Meeting Muskoka, Canada Sunday,
More informationSYNOPSIS. Issue Date: 17 Jan 2013
STELARA (ustekinumab) Clinical Study Report CNTO1275PSA3002 24-Week CSR SYNOPSIS Issue Date: 17 Jan 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research &
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More informationCharité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3
Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-blind, Monotherapy Study in Patients With Active Rheumatoid Arthritis With Intolerance or Inadequate Response to Methotrexate
More informationPublic observer slides
Public observer slides Lead team presentation Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple
More informationPsA. SIMPONI (golimumab) Rheumatoid arthritis. Psoriatic arthritis. Ankylosing spondylitis EFFICACY EFFICACY EFFICACY. QoL. QoL.
RA Rheumatoid arthritis PsA Psoriatic arthritis AS Ankylosing spondylitis EFFICACY EFFICACY EFFICACY QoL QoL QoL SAFETY SAFETY SAFETY EXPERIENCE EXPERIENCE EXPERIENCE SUMMARY SUMMARY SUMMARY Copyright
More informationImproved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial
Strand et al. Arthritis Research & Therapy (2018) 20:269 https://doi.org/10.1186/s13075-018-1769-7 RESEARCH ARTICLE Open Access Improved patient-reported outcomes in patients with psoriatic arthritis treated
More informationCoates et al. Arthritis Research & Therapy (2018) 20:272 (Continued on next page)
Coates et al. Arthritis Research & Therapy (2018) 20:272 https://doi.org/10.1186/s13075-018-1773-y RESEARCH Open Access Secukinumab provides sustained PASDASdefined remission in psoriatic arthritis and
More informationNational Doral, Miami, Florida 7:20 AM 8:20 AM, Ballroom B. Supported by an educational grant from Novartis Pharmaceuticals Corporation.
National Doral, Miami, Florida 7:20 AM 8:20 AM, Ballroom B Supported by an educational grant from Novartis Pharmaceuticals Corporation. Allan Gibofsky, MD, JD, MACR, FACP, FCLM Weill Medical College of
More informationPhilip Mease Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, Washington, USA.
Providence St. Joseph Health Providence St. Joseph Health Digital Commons Journal Articles and Abstracts 6-1-2018 improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary
More informationHorizon Scanning Centre January Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716
Horizon Scanning Centre January 2013 Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716 This briefing is based on information available at the time of research and a limited literature search.
More informationWhat is Cosentyx (secukinumab)?
What is Cosentyx (secukinumab)? Cosentyx is the first of a new class of medicines called interleukin- 17A (IL- 17A) inhibitors to be approved for the treatment of moderate- to- severe plaque psoriasis,
More informationESPONDILOARTROPATÍAS. Dr. Julio Ramírez García
ESPONDILOARTROPATÍAS Dr. Julio Ramírez García Bloque 1: Caracterización de los pacientes con SpA axial ABSTRACT NUMBER: 1509 Similarities and Differences between Non-Radiographic and Radiographic Axial
More informationCOSENTYX (secukinumab)
COSENTYX (secukinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationA Patient s Guide to. Treatments for Psoriatic Arthritis
A Patient s Guide to Treatments for Psoriatic Arthritis Who should read this guide? This guide is aimed at people with psoriatic arthritis (abbreviated as PsA), or those who care for a person with this
More informationISSN: (Print) (Online) Journal homepage:
mabs ISSN: 1942-0862 (Print) 1942-0870 (Online) Journal homepage: https://www.tandfonline.com/loi/kmab20 Certolizumab Pegol Niti Goel & Sue Stephens To cite this article: Niti Goel & Sue Stephens (2010)
More informationPsoriasis and Psoriatic Arthritis Treatment
n REPORT n Psoriasis and Psoriatic Arthritis Treatment Alan Menter, MD Overarching Principles of Psoriasis and Psoriatic Arthritis Treatment Several best practices have emerged to guide the management
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationA. Kopchev, S.Monov, D. Kyurkchiev, I.Ivanova, T. Georgiev (UMHAT St. Ivan Rilski, Medical University - Sofia, Bulgaria)
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 6 Issue 7 July 2017 PP. 08-12 Vascular endothelial growth factor (VEGF), cartilage oligomeric
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationGaps in the Treatment of Psoriasis and PsA for Systemic Therapy
Gaps in the Treatment of Psoriasis and PsA for Systemic Therapy Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Department of Dermatology Icahn School of Medicine at Mount Sinai Disclosure Mark
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationEfficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Rheumatol Ther (2018) 5:567 582 https://doi.org/10.1007/s40744-018-0131-5 ORIGINAL RESEARCH Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies Peter
More informationWelcome and Overview. Melodie Young, MSN, ANP-C Nurse Practitioner, Modern Dermatology Partner, Modern Research Associates Dallas, Texas
Welcome and Overview Melodie Young, MSN, ANP-C Nurse Practitioner, Modern Dermatology Partner, Modern Research Associates Dallas, Texas Advances in Biologic Therapies for Psoriasis April W. Armstrong,
More informationGender differences in effectiveness of treatment in rheumatic diseases
Gender differences in effectiveness of treatment in rheumatic diseases Irene van der Horst-Bruinsma Associate Professor Rheumatology Center of Excellence of Axial Spondyloarthritis ARC/VU University Medical
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ruperto N, Martini A. Current and future perspectives
More informationClinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1097-7 Program Prior Authorization/Notification Medication *Stelara (ustekinumab) *This program applies to the subcutaneous formulation
More informationBOARD CERTIFIED IN RHEUMATOLOGY NURSING
Inside this Issue ISSUE 3 VOLUME 3»»»» Which disease states are included within the broader family of the spondyloarthopathies? How do the primary characteristics of the spondyloarthopathies differ from
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More information- Clinical Background, Motivation and my Experience at F2F meeting
Predicting randomized clinical trial results with realworld evidence: A case study in the comparative safety of tofacitinib, adalimumab and etanercept in patients with rheumatoid arthritis - Clinical Background,
More informationNeil McHugh Royal National Hospital for Rheumatic Diseases University of Bath
Psoriatic arthritis Neil McHugh Royal National Hospital for Rheumatic Diseases University of Bath The Spondyloarthropathies Axial Spondyloarthropathy Peripheral joint arthritis Features Spondylitis Uveitis
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date:
Clinical Policy: (Taltz) Reference Number: ERX.SPA.122 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationapremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd.
apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd. 08 May 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationClinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date:
Clinical Policy: (Orencia) Reference Number: ERX.SPA.123 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPsoriasis. Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid
Psoriasis Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid PSORIASIS Psoriasis News. Topical treatment Calcipotriene/Betamethasone Dipropionate (Cal/BD) foam: In the real-world, Cal/BD
More informationWhat s New in the Treatment of Psoriasis
What s New in the Treatment of Psoriasis Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Mark Lebwohl is an
More informationTitle: The ideal target for psoriatic arthritis? Comparison of remission and low
Title: The ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real life cohort. Leonieke J.J. van Mens, MD 1, Marleen G.H. van de Sande, MD 1, PhD 1, Arno
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationFor Rheumatoid Arthritis
For Rheumatoid Arthritis APRIL 2017 NOTICE: On April 14, 2017 the FDA issued a complete response letter for baricitinib indicating that the FDA is unable to approve the application in its current form
More informationThe New and Emerging Agents: Dermatology
Psoriasis Treatment 2013: What is New and on the Horizon? Neil J Korman, MD, PhD Professor of Dermatology University Hospitals Case Medical Center Clinical Director Murdough Family Center for Psoriasis
More informationSIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Oxford Clinical Policy SIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION Policy Number: PHARMACY 292.4 T2 Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET SIMPONI Solution for Injection in a pre-filled syringe Solution for Injection in a pre-filled pen, SmartJect NAME OF MEDICINE SIMPONI Solution for Injection in a pre-filled syringe
More informationadalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott)
adalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott) 08 March 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationTherapeutic Advances for the Management of Patients with Psoriatic Arthritis
Therapeutic Advances for the Management of Patients with Psoriatic Arthritis Alan L. Epstein, MD Clinical Professor of Medicine Univ. of Penn. School of Medicine Disclosure of Conflicts of Interest Alan
More informationUstekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis
Arthritis Care & Research Vol. 68, No. 12, December 216, pp 1812 1822 DOI 1.12/acr.23 VC 216, The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of the American College
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationOrencia (abatacept) DRUG.00040
Market DC Orencia (abatacept) DRUG.00040 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Comments Quantity Limit Orencia (abatacept) - AGP, VA MCD only 4 vials per 28
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationTreatment of psoria.c arthri.s: Guidelines and beyond. Pascal RICHETTE Hôpital Lariboisière, Paris
Treatment of psoria.c arthri.s: Guidelines and beyond Pascal RICHETTE Hôpital Lariboisière, Paris The pa.ent: a 37 year- old man, with a history of psoriasis for 10 years Past history: - Dyslipidemia Current
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationPsoriatic arthritis (PsA) is a form of inflammatory
243 Psoriatic Arthritis Treatment Update Philip J. Mease, M.D. Psoriatic arthritis (PsA) is a form of inflammatory arthritis that occurs in approximately 10% to 30% of individuals with psoriasis, depending
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More information